HAMPTON, N.J., March 16, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, LLC (Nasdaq:BLPH) a clinical stage biotherapeutics company, today announced that it will preside over the ceremonial NASDAQ Stock Market Closing Bell on Tuesday, March 17, 2015, at 4:00 p.m. ET at the NASDAQ MarketSite in New York City. Jonathan Peacock, Chairman and Chief Executive Officer of Bellerophon Therapeutics, will ring the Closing Bell together with members of the senior management team.
Mr. Peacock noted, "We're grateful to our investors who are supporting us through the NASDAQ platform in developing important new therapies for patients with serious cardiopulmonary and cardiac diseases. We're a young company, but we're already getting started with our INOpulse Phase 3 trials for the treatment of Pulmonary Arterial Hypertension (PAH) and expect top line results for our international CE Mark registration trial for our bioabsorbable cardiac matrix (BCM) to prevent cardiac remodeling that often progresses to congestive heart failure for patients suffering large heart attacks."
A live webcast of the Closing Bell ceremony will begin at 3:50 p.m. ET and can be viewed via The MarketSite Webcam by launching the link: http://new.livestream.com/nasdaq/live.
Bellerophon Therapeutics LLC, is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse, one for the treatment of Pulmonary Arterial Hypertension (PAH) for which the company intends to commence Phase 3 clinical trials in the second half of 2015 and a second for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) which is in Phase 2 development. Bellerophon acquired exclusive worldwide rights to develop and commercialize the INOpulse programs in PAH, PH-COPD and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) from Ikaria, Inc. in February 2014 as part of Ikaria's spin-out of certain of its research and development assets and subsidiaries. Bellerophon's other program is bioabsorbable cardiac matrix, or BCM, which is being developed for the prevention of cardiac remodeling and subsequent chronic heart failure (CHF) following acute myocardial infarction, commonly known as a heart attack. BCM is currently in development in a placebo-controlled clinical trial designed to support CE mark registration in the European Union. This trial recently completed enrollment in December 2014, with 303 patients having completed the treatment procedure, and top line results are expected in mid-2015. Bellerophon has an exclusive worldwide license to BCM from BioLineRx Ltd.
CONTACT: At Bellerophon:
Manesh Naidu, Chief Business Officer
At Rx Communications Group:
Paula Schwartz (Investors)
Eric Goldman (Media)
Bellerophon Therapeutics LLC